niflumic acid   Click here for help

GtoPdb Ligand ID: 2439

Approved drug PDB Ligand Immunopharmacology Ligand
niflumic acid is an approved drug
Compound class: Synthetic organic
Comment: Niflumic acid is used clinically as an anti-inflammatory agent due to its action as a cyclooxygenase-2 (COX-2) inhibitor.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

niflumic acid is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 62.22
Molecular weight 282.06
XLogP 3.68
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F
Isomeric SMILES OC(=O)c1cccnc1Nc1cccc(c1)C(F)(F)F
InChI InChI=1S/C13H9F3N2O2/c14-13(15,16)8-3-1-4-9(7-8)18-11-10(12(19)20)5-2-6-17-11/h1-7H,(H,17,18)(H,19,20)
InChI Key JZFPYUNJRRFVQU-UHFFFAOYSA-N
References
1. Busch AE, Herzer T, Wagner CA, Schmidt F, Raber G, Waldegger S, Lang F. (1994)
Positive regulation by chloride channel blockers of IsK channels expressed in Xenopus oocytes.
Mol Pharmacol, 46 (4): 750-3. [PMID:7969055]
2. Dai L, Garg V, Sanguinetti MC. (2010)
Activation of Slo2.1 channels by niflumic acid.
J Gen Physiol, 135 (3): 275-95. [PMID:20176855]
3. Garg P, Sanguinetti MC. (2012)
Structure-activity relationship of fenamates as Slo2.1 channel activators.
Mol Pharmacol, 82 (5): 795-802. [PMID:22851714]
4. Hu H, Tian J, Zhu Y, Wang C, Xiao R, Herz JM, Wood JD, Zhu MX. (2010)
Activation of TRPA1 channels by fenamate nonsteroidal anti-inflammatory drugs.
Pflugers Arch, 459 (4): 579-92. [PMID:19888597]
5. Walker RL, Koh SD, Sergeant GP, Sanders KM, Horowitz B. (2002)
TRPC4 currents have properties similar to the pacemaker current in interstitial cells of Cajal.
Am J Physiol, Cell Physiol, 283 (6): C1637-45. [PMID:12388058]